Akorn Extends Lenders Standstill With Aim To Sell Company
Fourth Quarter Losses Narrow But Figures Miss Analyst Targets
Executive Summary
US generics company Akorn, which has been struggling since Germany’s Fresenius walked away from a $4.3bn merger three years ago, plans to put itself up for sale under an extended standstill agreement with lenders.
You may also be interested in...
Akorn Defaults On Loan Agreement After Sale Bid Falls Flat
Facing soaring legal costs stemming from its failed merger with Fresenius Kabi and burdened by substantial debt, Akorn elected to put itself up for sale earlier this year in order to help repay lenders. But the company has now defaulted on an agreement with its creditors after no bidder stepped up to the plate.
Deal Watch: Vir Partnering With Alnylam, WuXi On Coronavirus Treatments
US biotech expands 2017 collaboration with Alnylam and inks collaboration with WuXi. Plus deals involving AbbVie, Allergan, Amazon, Thermo Fisher, Qiagen, Boehringer Ingelheim, Trutino, Taiho, Arcus, Eisai, Fuji Yakuhin, Hikma, Glenmark, Hanmi, GC, Bayer, GW.
Akorn Considers Bankruptcy Filing
Buried within its financial disclosure of a standstill agreement with creditors until 7 February, Akorn disclosed that it is considering whether to file for bankruptcy protection in the US.